Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes.
暂无分享,去创建一个
[1] S. Yano,et al. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[2] T. Sugimoto,et al. Bone Mineral Density Is not Sensitive Enough to Assess the Risk of Vertebral Fractures in Type 2 Diabetic Women , 2007, Calcified Tissue International.
[3] M. Bouxsein,et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. , 2006, Bone.
[4] M. Saito,et al. Degree of Mineralization-related Collagen Crosslinking in the Femoral Neck Cancellous Bone in Cases of Hip Fracture and Controls , 2006, Calcified Tissue International.
[5] S. Cummings,et al. Thiazolidinedione use and bone loss in older diabetic adults. , 2006, The Journal of clinical endocrinology and metabolism.
[6] M. Saito,et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats , 2006, Osteoporosis International.
[7] M. Saito,et al. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture , 2006, Osteoporosis International.
[8] S. Mohan,et al. Serum Levels of Insulin-Like Growth Factor (IGF); IGF-Binding Proteins-3, -4, and -5; and Their Relationships to Bone Mineral Density and the Risk of Vertebral Fractures in Postmenopausal Women , 2006, Calcified Tissue International.
[9] T. Keaveny,et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. , 2005, Bone.
[10] P. Odetti,et al. Advanced Glycation End Products and Bone Loss during Aging , 2005, Annals of the New York Academy of Sciences.
[11] P. Vestergaard,et al. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk , 2005, Diabetologia.
[12] M. Barbagallo,et al. Collagen overglycosylation: a biochemical feature that may contribute to bone quality. , 2005, Biochemical and biophysical research communications.
[13] M. Plebani,et al. Pentosidine plasma levels and relation with metabolic control in diabetic patients. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[14] Y. Aso,et al. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. , 2005, Metabolism: clinical and experimental.
[15] P. Delmas,et al. The role of collagen in bone strength , 2005, Osteoporosis International.
[16] S. Kamohara,et al. Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. , 2003, Free radical biology & medicine.
[17] M. Fukunaga,et al. Fracture Prediction From Bone Mineral Density in Japanese Men and Women , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] C. M. Agrawal,et al. Age-related changes in the collagen network and toughness of bone. , 2002, Bone.
[19] A. Hofman,et al. The Incidence of Vertebral Fractures in Men and Women: The Rotterdam Study , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] Tsutomu Sanaka,et al. Plasma Pentosidine Levels Measured by a Newly Developed Method Using ELISA in Patients with Chronic Renal Failure , 2002, Nephron.
[21] J. D. Luna,et al. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[22] R. Cumming,et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. , 2001, Diabetes care.
[23] A. Folsom,et al. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. , 2001, Diabetes care.
[24] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[25] S. Cummings,et al. Older women with diabetes have an increased risk of fracture: a prospective study. , 2001, The Journal of clinical endocrinology and metabolism.
[26] J. Lutterman,et al. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology , 2000, Journal of endocrinological investigation.
[27] F. Escobar-Jiménez,et al. Intensive Insulin Therapy and Bone Mineral Density in Type 1 Diabetes Mellitus: A Prospective Study , 2000, Osteoporosis International.
[28] T. Rönnemaa,et al. Bone mineral density in patients with type 1 and type 2 diabetes. , 1999, Diabetes care.
[29] L. Forsén,et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey , 1999, Diabetologia.
[30] S. Genuth,et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.
[31] T. Miyata,et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. , 1998, Journal of the American Society of Nephrology : JASN.
[32] C van Ypersele de Strihou,et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.
[33] M. Brownlee,et al. Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.
[34] A. McElduff,et al. Diabetes Control and Complications Trial , 1993 .
[35] M. Nevitt,et al. Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[36] V. Monnier,et al. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. , 1993, Kidney international.
[37] J. Baynes,et al. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.
[38] V. Monnier,et al. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. , 1989, The Journal of biological chemistry.
[39] A. Cerami,et al. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.